Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.

This review details the preclinical and early clinical activity and side effects of docetaxel, showing its significant effectiveness against various cancers with neutropenia as a major side effect.

This study found that cefazolin-loaded silica nanoparticles embedded in polycaprolactone nanofibers successfully inhibited Staphylococcus aureus growth while maintaining stem cell viability, suggesting their potential use in wound healing.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that combining celecoxib with chemotherapy improved overall survival, disease-free survival, and quality of life in gastric cancer patients with positive COX-2 expression without increasing adverse events.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

In this study, methotrexate therapy with or without corticosteroids showed similar efficacy and safety in treating patients with lichen planopilaris, with no significant differences in the primary outcome or adverse effects between the two groups.

This study found that while 51.3% of severe alopecia areata patients achieved significant hair regrowth with intravenous methylprednisolone, oral Janus kinase inhibitors may benefit those who do not respond to this treatment.

This article rebuts a previous rejection of corticosteroid therapy for alopecia areata, reporting successful treatment in multiple patients with systemic and intralesional steroids and minimal side effects.

This review explores various theories of colorectal cancer stem cell biology and highlights the need for better identification and targeting of these cells to advance treatment strategies, but reports no new clinical findings.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

This study observed that intradermal injections of Betamethasone were more effective than topical Clobetazole for treating alopecia areata in children, while Tofacitinib showed higher efficacy in those with atopic dermatitis.

This study observed that applying a GMP-grade botanical extract to the scalp increased Bcl-2 levels, potentially preventing premature hair follicle apoptosis in chemotherapy and radiotherapy-induced alopecia.

MEBO ointment helps activate and grow skin stem cells for burn healing.

This article discusses the development of non-myeloablative stem cell transplants, which may expand the safe treatment range of allogeneic SCT, but presents no new clinical results.

This review discusses the efficacy and safety of cyclosporine, methotrexate, and acitretin for managing psoriasis and reports no new clinical results; cyclosporine showed a rapid onset for severe psoriasis, methotrexate highlighted liver concerns, and acitretin was noted for its non-immunosuppressive benefits.

This study found that cucurbitacin I from bitter melon most effectively inhibited the growth of lung cancer cells and promoted hair cell growth in cell cultures.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This study found that topical bortezomib increased cell proliferation in hair follicles and sebaceous glands in mice and may activate hair keratin gene expression through GATA-3 transcription factors.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.